Canada Vaccines Market Overview, 2028

Canada has emerged as a global model for effective vaccine distribution and immunisation programs. The country's vaccine market is characterised by a commitment to public health, government support, and a comprehensive approach to protecting its population from vaccine-preventable diseases. One of the cornerstones of Canada's success in the vaccine market is its government-led immunisation programs. These programmes are administered at both the federal and provincial levels, ensuring that vaccines are accessible to all Canadians. The National Advisory Committee on Immunisation (NACI) provides evidence-based recommendations, while provinces and territories implement vaccination schedules. Canada's immunisation efforts cover individuals of all ages, from infants to the elderly. Routine immunisation schedules ensure that children receive vaccines on time, protecting them from diseases like measles, mumps, rubella, and diphtheria. Additionally, vaccines for influenza, pneumonia, and shingles are readily available for adults and seniors. Canada has been proactive in responding to global health threats. During the COVID-19 pandemic, the country played a pivotal role in vaccine development and distribution. Vaccines, including those from domestic manufacturers and international collaborations, were swiftly administered to Canadians, contributing to a high vaccination rate. Canada is home to leading research institutions and pharmaceutical companies engaged in vaccine research and development. The country has made significant contributions to the development of vaccines against various diseases, including those with global implications.

According to the research report, "Canada Vaccines Market Outlook, 2028," published by Bonafide Research, the Canada Vaccines market is anticipated to add more than 690 Million by 2023–28. There is a growing awareness of the importance of vaccination among the global population. This is due to factors such as public health campaigns, social media, and the increasing availability of information about vaccines online and in print. Governments around the world are providing strong support for vaccination. This includes funding for vaccine research and development as well as programmes to promote vaccination coverage. New vaccines are being developed all the time, which is expanding the global vaccine market. Vaccines are a cornerstone of preventive healthcare. They offer a proactive approach to disease prevention, reducing the risk of infection and the subsequent development of serious illnesses. This preventive aspect drives demand as individuals and healthcare systems prioritise avoiding diseases. International travellers often require vaccines to protect against diseases prevalent in their destination countries. Compliance with international health regulations and travel-related vaccinations drives demand for specific vaccines. The National Immunisation Strategy is a comprehensive approach to vaccination in Canada. It focuses on improving immunisation coverage rates, enhancing vaccine safety monitoring, and promoting public awareness of the importance of vaccination. The strategy is a collaborative effort between federal, provincial, and territorial governments. PHAC is a federal agency responsible for public health initiatives, including immunization. PHAC provides guidance on vaccine recommendations, supports research on vaccine safety and efficacy, and coordinates responses to vaccine-preventable disease outbreaks. Canada actively participates in global vaccination initiatives. It supports organisations like Gavi, the Vaccine Alliance, which helps ensure access to vaccines in low- and middle-income countries.

Based on the technology types, they include conjugated vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In Canada, the inactivated and subunit vaccines are a growing market. Inactivated and subunit vaccines are known for their safety profiles. They are composed of components or inactivated forms of the pathogen, making them less likely to cause adverse effects. Canadians prioritise vaccine safety, and these technologies align with their preferences. Many inactivated and subunit vaccines are suitable for paediatric use. Given Canada's commitment to childhood immunisation, these vaccines play a crucial role in protecting young children from diseases like polio, hepatitis B, and influenza. Canada has a robust national immunisation programme that covers a wide range of vaccine-preventable diseases. Inactivated and subunit vaccines are integral to this programme, ensuring that Canadians receive comprehensive protection. Canada actively participates in global health initiatives and contributes to vaccine distribution efforts in low- and middle-income countries. Inactivated and subunit vaccines are often included in these initiatives due to their suitability for diverse populations. Inactivated and subunit vaccines are effective in preventing diseases caused by a range of pathogens, including viruses and bacteria. Canadians value disease prevention, making these vaccines a priority for public health.

According to the end user segment, which includes paediatric vaccines and adult vaccines, in Canada, adult vaccines are a growing market. Canadian healthcare authorities, such as the National Advisory Committee on Immunisation (NACI), have expanded their vaccine recommendations to include a wider range of vaccines for adults. These recommendations have raised awareness about the importance of adult immunization. Some vaccine-preventable diseases, such as influenza, shingles, and pneumonia, pose a significant risk to adults, particularly older individuals and those with underlying health conditions. The recognition of these risks has motivated adults to seek vaccination. Public health campaigns and educational initiatives have increased awareness about the benefits of adult vaccination. These campaigns provide information on recommended vaccines for adults and emphasise the importance of staying up-to-date on vaccinations. Canada has an ageing population, and older adults are more susceptible to certain vaccine-preventable diseases. The growing proportion of older adults has contributed to increased demand for vaccines like the influenza and shingles vaccines.

Based on the route of administration, they are segmented into intramuscular and subcutaneous administration, oral administration, and others. In Canada, intramuscular and subcutaneous vaccinations lead the market. Canada has a robust routine immunisation programme that recommends a schedule of vaccinations for various age groups. Many of these vaccines are administered via the IM or SC route, including vaccines for infants, children, adolescents, and adults. These programmes contribute to a consistent demand for vaccines delivered through these methods. IM and SC administration are well-established and proven methods for vaccine delivery. These routes are known for their safety and efficacy in eliciting a strong immune response, which is crucial for protecting against infectious diseases. Canada's vaccine market includes a wide range of vaccines, including those for preventable diseases such as influenza, hepatitis, measles, mumps, rubella, and more. Many of these vaccines are administered through IM or SC injection. According to the report, types are segmented into multivalent vaccines and monovalent vaccines, among them in Canada. Multivalent vaccines are a leading market. Multivalent vaccines combine protection against multiple diseases into a single vaccine, reducing the number of shots needed. This is especially important for infants and young children, who require numerous vaccinations. Parents and healthcare providers prefer combination vaccines as they simplify the vaccination schedule. Fewer injections increase the likelihood of individuals and parents adhering to the recommended vaccination schedule. This results in higher vaccination rates and better public health outcomes.



In terms of disease types, they include the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus, the human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella, mumps, and others. In Canada, the human papilloma virus will grow with the highest rate of growth. Cancer is growing. Ongoing research and development efforts in the fields of cancer immunotherapy and vaccine development have led to the creation of novel cancer vaccines. These vaccines are designed to stimulate the body's immune system to target and destroy cancer cells. Canada is actively involved in conducting clinical trials for cancer vaccines. These trials evaluate the safety and efficacy of new cancer vaccines, which can lead to their approval and inclusion in cancer treatment protocols. The Canadian government has been supportive of cancer research and treatment initiatives. Funding and resources have been allocated to support cancer vaccine development and access. Increased public awareness about the potential benefits of cancer vaccines has led to greater interest and demand for these treatments. As people become more informed about cancer prevention and treatment options, the market for cancer vaccines may grow.

Distribution channels include hospital pharmacy, retail pharmacy, and institutional sales. In Canada, retail pharmacies are a growing market. Retail pharmacies are widely distributed across Canada, including in urban, suburban, and rural areas. This extensive network of pharmacies ensures that vaccines are readily accessible to a large portion of the population. Pharmacists are highly trained healthcare professionals who can administer vaccines and provide information about vaccine recommendations. Their expertise contributes to vaccine safety and patient education. Retail pharmacies offer a wide range of vaccines, including routine immunisations, travel vaccines, and seasonal flu shots. This diversity of vaccines makes retail pharmacies a one-stop destination for vaccination needs. Many retail pharmacies actively engage in community outreach programmes to promote vaccination. They collaborate with local health authorities to host vaccination clinics and educational events.

Considered in this report:
• Geography: Canada
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• Canada Vaccines market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By Route of Administration
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

By Disease
• Rotavirus
• Pneumococcal diseases
• Cancer
• Influenza
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Hepatitis
• Shingles
• Meningococcal diseases
• Varicella (Chicken Pox)
• Mumps
• Others

By Type
• Multivalent vaccines
• Monovalent vaccines

By End-User Type
• Paediatrics
• Adults

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.